Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
出版年份 2018 全文链接
标题
Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
作者
关键词
-
出版物
MEDICINAL RESEARCH REVIEWS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-09-15
DOI
10.1002/med.21530
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective
- (2018) Danfeng Shi et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
- (2018) Poonam K. Panjwani et al. HUMAN PATHOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- In situandin silicokinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network
- (2017) Kaitao Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Clinical immunogenicity of the d -amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments
- (2017) Mark A. Kroenke et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Challenges for the pharmaceutical technical development of protein coformulations
- (2017) Claudia Mueller et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Anti-PD-L1 peptide improves survival in sepsis
- (2017) Yuichiro Shindo et al. JOURNAL OF SURGICAL RESEARCH
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
- (2017) Petros Fessas et al. SEMINARS IN ONCOLOGY
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
- (2017) Chunlin Li et al. Cancer Immunology Research
- Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
- (2017) William K. Decker et al. Frontiers in Immunology
- Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy
- (2017) Eszter Lázár-Molnár et al. EBioMedicine
- Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
- (2017) Fei Zhang et al. Cell Discovery
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- PD-1/PD-L1 binding studies using microscale thermophoresis
- (2017) Romain Magnez et al. Scientific Reports
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- (2016) M. Chatterjee et al. ANNALS OF ONCOLOGY
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
- (2016) Kefang Liu et al. CELL RESEARCH
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
- (2016) Aude G. Chapuis et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
- (2016) Antoine Millet et al. MEDICINAL RESEARCH REVIEWS
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
- (2016) Roberta Pascolutti et al. STRUCTURE
- Magneto-nanosensor platform for probing low-affinity protein–protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction
- (2016) Jung-Rok Lee et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
- (2016) Shoichiro Horita et al. Scientific Reports
- PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis
- (2016) Lei Shen et al. Scientific Reports
- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
- (2015) C Ciccarese et al. Expert Opinion on Drug Metabolism & Toxicology
- Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
- (2015) Yuki Katsuya et al. LUNG CANCER
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases
- (2015) Hojabr Kakavand et al. MODERN PATHOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Small molecule drugs with immunomodulatory effects in cancer
- (2015) Adrian G Murphy et al. Human Vaccines & Immunotherapeutics
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
- (2015) André P Fay et al. Journal for ImmunoTherapy of Cancer
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- Strategic Approaches to Optimizing Peptide ADME Properties
- (2014) Li Di AAPS Journal
- Small Molecule Modulators of Protein–Protein Interactions: Selected Case Studies
- (2014) Madhu Aeluri et al. CHEMICAL REVIEWS
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
- (2014) Yannick Bulliard et al. IMMUNOLOGY AND CELL BIOLOGY
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of NF- B1 by OX40 Contributes to Antigen-Driven T Cell Expansion and Survival
- (2014) J. Song et al. JOURNAL OF IMMUNOLOGY
- Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis
- (2014) J. O. Jurado et al. JOURNAL OF IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Hot spots in protein–protein interfaces: Towards drug discovery
- (2014) Engin Cukuroglu et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Regulation of A1 by OX40 Contributes to CD8+ T Cell Survival and Anti-Tumor Activity
- (2013) Fengyang Lei et al. PLoS One
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
- (2012) Lukas Baitsch et al. PLoS One
- Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
- (2011) Véronique Corbière et al. CANCER RESEARCH
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
- (2011) A. M. Paterson et al. JOURNAL OF IMMUNOLOGY
- The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
- (2011) J. Yang et al. JOURNAL OF IMMUNOLOGY
- PD-L2 is expressed on activated human T cells and regulates their function
- (2011) Nassima Messal et al. MOLECULAR IMMUNOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- Targeting protein–protein interactions for therapeutic intervention: a challenge for the future
- (2010) Giovanna Zinzalla et al. Future Medicinal Chemistry
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- A dimeric structure of PD-L1: functional units or evolutionary relics?
- (2010) Yong Chen et al. Protein & Cell
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
- (2009) A. W. Pawluczkowycz et al. JOURNAL OF IMMUNOLOGY
- Principles of Protein−Protein Interactions: What are the Preferred Ways For Proteins To Interact?
- (2008) Ozlem Keskin et al. CHEMICAL REVIEWS
- CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
- (2008) Kavita V. Shah et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interaction of human PD-L1 and B7-1
- (2008) Manish J. Butte et al. MOLECULAR IMMUNOLOGY
- Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek
- (2008) G. J. Freeman PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search